For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Search Posts
Letters
CEI Joins Coalition Letter on Fixed Drug Pricing
Dear Republican Members of the House and Senate, We represent fiscal conservatives and free market activists from across the country, and we are concerned about…
Inside Sources
Federal Children’s Environmental Health Grants Used to Peddle Junk Science
For more than two decades, the federal government has doled out millions of dollars to fund university-based “children’s environmental health centers.” These centers operate under…
Fox News
Pelosi, Progressive Caucus Clash over Drug Pricing Legislation
Fox News cites Research Fellow Patrick Hedger on Nancy Pelosi’s proposed “Lower Drug Costs Now Act.” But according to the right-leaning Competitive Enterprise…
Townhall
The Black Market Is the Real Problem with Vaping
Townhall cites Senior Fellow Michelle Minton on e-cigarettes and the black market. But, as Michelle Minton of the Competitive Enterprise Institute stated after…
News Release
House Bill Setting Price Controls on Medicines Would Endanger Patients, Harm Innovation
House Speaker Nancy Pelosi and Majority Leader Steny Hoyer plan to bring H.R. 3, the Lower Drug Costs Now Act, to the floor for a…
Real Clear Markets
With Drug Pricing, Bipartisanship Isn’t an Excuse to Violate the Laws of Economics
In an age of intense political polarization, some may assume anything that House Speaker Nancy Pelosi and President Donald Trump even marginally agree on has…